Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CLpro

Usman Bacha, Jennifer Barrila, Sandra B. Gabelli, Yoshiaki Kiso, L. Mario Amzel, Ernesto Freire

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Coronaviruses comprise a large group of RNA viruses with diverse host specificity. The emergence of highly pathogenic strains like the SARS coronavirus (SARS-CoV), and the discovery of two new coronaviruses, NL-63 and HKU1, corroborates the high rate of mutation and recombination that have enabled them to cross species barriers and infect novel hosts. For that reason, the development of broad-spectrum antivirals that are effective against several members of this family is highly desirable. This goal can be accomplished by designing inhibitors against a target, such as the main protease 3CL pro (Mpro), which is highly conserved among all coronaviruses. Here 3CLpro derived from the SARS-CoV was used as the primary target to identify a new class of inhibitors containing a halomethyl ketone warhead. The compounds are highly potent against SARS 3CLpro with Ki's as low as 300 nm. The crystal structure of the complex of one of the compounds with 3CLpro indicates that this inhibitor forms a thioether linkage between the halomethyl carbon of the warhead and the catalytic Cys 145. Furthermore, Structure Activity Relationship (SAR) studies of these compounds have led to the identification of a pharmacophore that accurately defines the essential molecular features required for the high affinity.

Original languageEnglish (US)
Pages (from-to)34-49
Number of pages16
JournalChemical Biology and Drug Design
Volume72
Issue number1
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Lead compounds
Coronavirus
Sulfides
Ketones
Viruses
SARS Virus
Antiviral Agents
Peptide Hydrolases
Carbon
Crystal structure
RNA
Host Specificity
RNA Viruses
Mutation Rate
Structure-Activity Relationship
Genetic Recombination

Keywords

  • Biophysical chemistry
  • Calorimetric techniques
  • Drug design
  • Drug discovery
  • Protease and ligands (substrate/inhibitor)

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CLpro . / Bacha, Usman; Barrila, Jennifer; Gabelli, Sandra B.; Kiso, Yoshiaki; Mario Amzel, L.; Freire, Ernesto.

In: Chemical Biology and Drug Design, Vol. 72, No. 1, 07.2008, p. 34-49.

Research output: Contribution to journalArticle

Bacha, Usman ; Barrila, Jennifer ; Gabelli, Sandra B. ; Kiso, Yoshiaki ; Mario Amzel, L. ; Freire, Ernesto. / Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CLpro In: Chemical Biology and Drug Design. 2008 ; Vol. 72, No. 1. pp. 34-49.
@article{1b5a4212430b46d9aaaaf7b983530c81,
title = "Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CLpro",
abstract = "Coronaviruses comprise a large group of RNA viruses with diverse host specificity. The emergence of highly pathogenic strains like the SARS coronavirus (SARS-CoV), and the discovery of two new coronaviruses, NL-63 and HKU1, corroborates the high rate of mutation and recombination that have enabled them to cross species barriers and infect novel hosts. For that reason, the development of broad-spectrum antivirals that are effective against several members of this family is highly desirable. This goal can be accomplished by designing inhibitors against a target, such as the main protease 3CL pro (Mpro), which is highly conserved among all coronaviruses. Here 3CLpro derived from the SARS-CoV was used as the primary target to identify a new class of inhibitors containing a halomethyl ketone warhead. The compounds are highly potent against SARS 3CLpro with Ki's as low as 300 nm. The crystal structure of the complex of one of the compounds with 3CLpro indicates that this inhibitor forms a thioether linkage between the halomethyl carbon of the warhead and the catalytic Cys 145. Furthermore, Structure Activity Relationship (SAR) studies of these compounds have led to the identification of a pharmacophore that accurately defines the essential molecular features required for the high affinity.",
keywords = "Biophysical chemistry, Calorimetric techniques, Drug design, Drug discovery, Protease and ligands (substrate/inhibitor)",
author = "Usman Bacha and Jennifer Barrila and Gabelli, {Sandra B.} and Yoshiaki Kiso and {Mario Amzel}, L. and Ernesto Freire",
year = "2008",
month = "7",
doi = "10.1111/j.1747-0285.2008.00679.x",
language = "English (US)",
volume = "72",
pages = "34--49",
journal = "Chemical Biology and Drug Design",
issn = "1747-0277",
publisher = "Blackwell",
number = "1",

}

TY - JOUR

T1 - Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CLpro

AU - Bacha, Usman

AU - Barrila, Jennifer

AU - Gabelli, Sandra B.

AU - Kiso, Yoshiaki

AU - Mario Amzel, L.

AU - Freire, Ernesto

PY - 2008/7

Y1 - 2008/7

N2 - Coronaviruses comprise a large group of RNA viruses with diverse host specificity. The emergence of highly pathogenic strains like the SARS coronavirus (SARS-CoV), and the discovery of two new coronaviruses, NL-63 and HKU1, corroborates the high rate of mutation and recombination that have enabled them to cross species barriers and infect novel hosts. For that reason, the development of broad-spectrum antivirals that are effective against several members of this family is highly desirable. This goal can be accomplished by designing inhibitors against a target, such as the main protease 3CL pro (Mpro), which is highly conserved among all coronaviruses. Here 3CLpro derived from the SARS-CoV was used as the primary target to identify a new class of inhibitors containing a halomethyl ketone warhead. The compounds are highly potent against SARS 3CLpro with Ki's as low as 300 nm. The crystal structure of the complex of one of the compounds with 3CLpro indicates that this inhibitor forms a thioether linkage between the halomethyl carbon of the warhead and the catalytic Cys 145. Furthermore, Structure Activity Relationship (SAR) studies of these compounds have led to the identification of a pharmacophore that accurately defines the essential molecular features required for the high affinity.

AB - Coronaviruses comprise a large group of RNA viruses with diverse host specificity. The emergence of highly pathogenic strains like the SARS coronavirus (SARS-CoV), and the discovery of two new coronaviruses, NL-63 and HKU1, corroborates the high rate of mutation and recombination that have enabled them to cross species barriers and infect novel hosts. For that reason, the development of broad-spectrum antivirals that are effective against several members of this family is highly desirable. This goal can be accomplished by designing inhibitors against a target, such as the main protease 3CL pro (Mpro), which is highly conserved among all coronaviruses. Here 3CLpro derived from the SARS-CoV was used as the primary target to identify a new class of inhibitors containing a halomethyl ketone warhead. The compounds are highly potent against SARS 3CLpro with Ki's as low as 300 nm. The crystal structure of the complex of one of the compounds with 3CLpro indicates that this inhibitor forms a thioether linkage between the halomethyl carbon of the warhead and the catalytic Cys 145. Furthermore, Structure Activity Relationship (SAR) studies of these compounds have led to the identification of a pharmacophore that accurately defines the essential molecular features required for the high affinity.

KW - Biophysical chemistry

KW - Calorimetric techniques

KW - Drug design

KW - Drug discovery

KW - Protease and ligands (substrate/inhibitor)

UR - http://www.scopus.com/inward/record.url?scp=45449096521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45449096521&partnerID=8YFLogxK

U2 - 10.1111/j.1747-0285.2008.00679.x

DO - 10.1111/j.1747-0285.2008.00679.x

M3 - Article

VL - 72

SP - 34

EP - 49

JO - Chemical Biology and Drug Design

JF - Chemical Biology and Drug Design

SN - 1747-0277

IS - 1

ER -